Panacea Biotec has secured a major legal victory in its prolonged tax litigation battle, with the Income Tax Appellate Tribunal (ITAT) New Delhi delivering a comprehensive favorable ruling that eliminates a substantial tax demand of ₹329.49 Crore. The tribunal's decision addresses appeals spanning Assessment Years 2005-06 to 2012-13, marking the resolution of a complex tax dispute that has persisted for over a decade.

ITAT Ruling Details

The Income Tax Appellate Tribunal's comprehensive order addressed multiple appeals from both the tax authorities and the Company. The tribunal's decision encompassed three critical rulings that collectively favored Panacea Biotec across all contested assessment years, eliminating all expense disallowances that had been imposed by the tax authorities.

The DCIT appeals were filed against orders from the Commissioner of Income Tax (Appeals), New Delhi, arising from distinct assessment orders passed under sections 148/143(3) of the Income Tax Act. The Company's successful appeals were against orders from CIT Appeals, stemming from assessment orders under sections 153A/143(3) of the Act.

Financial Impact and Tribunal Order Confirmation

The tribunal's ruling delivers substantial financial relief to Panacea Biotec by eliminating the entire tax demand that had been raised by the Assessing Officer. The Company has confirmed that the tribunal order specifically deletes all disallowances of expenses across the contested assessment years, providing comprehensive relief from the disputed tax liability totaling 3.29 billion rupees.

The ruling effectively nullifies substantial contingent tax liabilities and potential penalty exposures that had been associated with these assessment years. This comprehensive relief removes a significant financial overhang that had persisted across multiple fiscal periods, potentially improving the Company's financial position and reducing regulatory uncertainties.

Regulatory Compliance and Disclosure

Panacea Biotec disclosed this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company received the ITAT order and promptly informed the stock exchanges about this material development.

The disclosure confirms that the litigation did not involve key management personnel, promoters, or ultimate persons in control of the Company. Additionally, the resolution did not involve any settlement arrangements, compensation payments, or penalties, as the tribunal ruled entirely in favor of the Company across all contested matters.

Assessment Years and Legal Framework

The disputed assessments covered eight consecutive years from 2005-06 to 2012-13, representing a comprehensive challenge to the Company's tax positions across nearly a decade of operations. The original assessment orders were passed under various sections of the Income Tax Act, including sections 148, 143(3), and 153A, indicating the scope and complexity of the tax authorities' examination.

The successful resolution of these appeals demonstrates Panacea Biotec's ability to defend its tax positions effectively through the appellate process. The tribunal's decision to quash the assessment orders entirely, rather than merely reducing the demands, provides the Company with complete relief from the contested tax liabilities and associated compliance burdens.

Panacea Biotec Limited has received an income tax demand order of ₹10.23 crore for Assessment Year 2016-17, the company disclosed in a regulatory filing on March 06, 2026. The demand was issued by the Office of the Deputy Commissioner of Income Tax, Central Circle 29, Delhi under Section 156 of the Income Tax Act, 1961.

Demand Order Details

The income tax demand stems from disallowances of certain expenditures made by the Assessing Officer. The company received the demand order dated March 01, 2026, which includes interest on account of additions made in the Assessment Order for Assessment Year 2016-17.

Nature of Violations

The tax demand arose from specific violations identified by the income tax authorities. Deductions were disallowed under Section 37 of the Income Tax Act by the Assessing Officer due to incorrect categorization of certain expenses. These expenses are alleged to be in violation of Medical Council of India regulations, leading to the substantial demand against the pharmaceutical company.

Company's Response and Legal Strategy

Panacea Biotec has strongly contested the income tax demand, describing it as non-maintainable. The company stated that the demand fails to account for its revised tax filings, which reflect no taxable income or tax liability due to the availability of brought-forward losses.

The company's planned legal recourse includes:

• Filing a rectification application with the income tax department
• Appealing before the relevant appellate authority
• Taking all necessary legal measures to contest the demand

Expected Impact on Operations

Despite the significant monetary value of the demand, Panacea Biotec does not anticipate any substantial impact on its financial, operational, or other business activities. The company's assessment suggests that the demand lacks merit based on its tax position and available legal remedies.

The disclosure was made pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring transparency with stakeholders regarding material developments affecting the company.